VBI Financial Statements From 2010 to 2024

VBIV Stock  USD 0.59  0.02  3.28%   
VBI Vaccines financial statements provide useful quarterly and yearly information to potential VBI Vaccines investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on VBI Vaccines financial statements helps investors assess VBI Vaccines' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting VBI Vaccines' valuation are summarized below:
Gross Profit
-10.2 M
Market Capitalization
17.3 M
Enterprise Value Revenue
4.1349
Revenue
8.7 M
Earnings Share
(6.03)
There are over one hundred nineteen available fundamental trend indicators for VBI Vaccines, which can be analyzed over time and compared to other ratios. All traders should should double-check VBI Vaccines' current fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. At this time, VBI Vaccines' Working Capital is fairly stable compared to the past year. Enterprise Value is likely to climb to about 57 M in 2024, whereas Market Cap is likely to drop slightly above 8.7 M in 2024.

VBI Vaccines Total Revenue

9.12 Million

Check VBI Vaccines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VBI main balance sheet or income statement drivers, such as Interest Expense of 8.5 M, Selling General Administrative of 44.3 M or Total Revenue of 9.1 M, as well as many exotic indicators such as Price To Sales Ratio of 1.0, Dividend Yield of 0.0 or PTB Ratio of 0.66. VBI financial statements analysis is a perfect complement when working with VBI Vaccines Valuation or Volatility modules.
  
This module can also supplement VBI Vaccines' financial leverage analysis and stock options assessment as well as various VBI Vaccines Technical models . Check out the analysis of VBI Vaccines Correlation against competitors.
For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.

VBI Vaccines Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets73.5 M87 M128.4 M
Very volatile
Total Stockholder Equity7.2 M7.5 M94 M
Slightly volatile
Property Plant And Equipment Net21.9 M11.9 M37.9 M
Slightly volatile
Cash28.9 M23.7 M45.3 M
Slightly volatile
Non Current Assets Total42.9 M50.7 M74.8 M
Pretty Stable
Non Currrent Assets OtherM1.2 M1.6 M
Slightly volatile
Cash And Short Term Investments31.5 M23.7 M49.4 M
Slightly volatile
Common Stock Shares Outstanding16.4 M15.6 M4.7 M
Slightly volatile
Liabilities And Stockholders Equity73.5 M87 M128.4 M
Very volatile
Other Current Assets2.9 M2.8 M1.4 M
Slightly volatile
Property Plant And Equipment Gross27.7 M22.3 M35.8 M
Slightly volatile
Total Current Assets33 M36.2 M53.7 M
Slightly volatile
Total Current Liabilities79.5 M75.7 M21.4 M
Slightly volatile
Accounts Payable6.8 M6.4 M3.1 M
Slightly volatile
Net Receivables1.3 M1.3 M314.6 K
Slightly volatile
Non Current Liabilities Total3.5 M3.7 M14.2 M
Pretty Stable
Short and Long Term Debt Total55.7 M53 M20.5 M
Slightly volatile
Short Term Debt54.3 M51.7 M12.6 M
Slightly volatile
Common Stock Total Equity260.5 M508.7 M255.8 M
Slightly volatile
Common Stock247.1 M454.2 M252.8 M
Slightly volatile
Long Term Debt59 M56.2 M23.2 M
Slightly volatile
Intangible Assets47.5 M36.5 M34.9 M
Slightly volatile
Property Plant Equipment14.8 M14.1 M6.1 M
Slightly volatile
Other Liabilities2.7 M3.1 M2.3 M
Slightly volatile
Short and Long Term Debt61.3 M58.4 M24.2 M
Slightly volatile
Current Deferred Revenue11.4 M10.9 MM
Slightly volatile
Capital Surpluse75.2 M103.5 M65.2 M
Slightly volatile
Good Will1.1 M1.1 M5.8 M
Slightly volatile
Long Term Debt Total59 M56.2 M22.2 M
Slightly volatile
Deferred Long Term Liabilities535.2 K602.1 K655.6 K
Slightly volatile
Non Current Liabilities Other4.9 M5.9 M2.9 M
Slightly volatile
Net Invested Capital98.7 M58.3 M125.4 M
Pretty Stable
Capital Stock416.8 M454.2 M310.8 M
Slightly volatile
Capital Lease Obligations2.5 M2.3 M1.8 M
Slightly volatile

VBI Vaccines Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative44.3 M42.1 M19.5 M
Slightly volatile
Other Operating Expenses67.2 M64 M37.2 M
Slightly volatile
Total Operating Expenses52 M49.5 M30.7 M
Slightly volatile
Depreciation And Amortization2.1 MM1.3 M
Slightly volatile
Selling And Marketing Expenses2.4 M2.3 M1.7 M
Slightly volatile
Cost Of Revenue15.2 M14.5 M7.7 M
Slightly volatile
Research Development15.8 M9.3 M11.8 M
Slightly volatile
Interest Income2.1 MM1.7 M
Slightly volatile
Reconciled Depreciation1.6 MM1.1 M
Slightly volatile
Non RecurringM5.7 M6.2 M
Slightly volatile

VBI Vaccines Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow65.8 M62.6 M44.8 M
Slightly volatile
Other Non Cash Items32.8 M31.3 M11.1 M
Slightly volatile
Capital Expenditures1.3 M867 K2.1 M
Very volatile
Total Cash From Financing Activities22.9 M22.7 M34.1 M
Slightly volatile
End Period Cash Flow26.8 M23.7 M45.2 M
Slightly volatile
Depreciation2.1 MM928.9 K
Slightly volatile
Stock Based Compensation4.4 M6.7 M4.6 M
Pretty Stable
Sale Purchase Of Stock13.1 K13.8 K26 M
Pretty Stable
Net Borrowings23.5 M22.4 M8.5 M
Slightly volatile
Change To Netincome46.5 M44.3 M12.5 M
Slightly volatile
Exchange Rate Changes188.8 K118.8 K232 K
Slightly volatile
Issuance Of Capital Stock35.9 M23.9 M45.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.01.0538163
Pretty Stable
PTB Ratio0.661.21551.5429
Slightly volatile
Days Sales Outstanding50.6453.308557.5 K
Slightly volatile
Book Value Per Share0.460.4834201
Slightly volatile
Invested Capital7.47.04661.192
Slightly volatile
Average Payables301.2 K286.8 K290.5 K
Pretty Stable
Stock Based Compensation To Revenue0.730.76723.614
Slightly volatile
PB Ratio0.661.21551.5429
Slightly volatile
Inventory Turnover1.621.70571.4 T
Slightly volatile
Days Of Inventory On Hand225214107
Slightly volatile
Payables Turnover2.142.25427.1539
Slightly volatile
Sales General And Administrative To Revenue4.614.854115.0968
Slightly volatile
Research And Ddevelopement To Revenue1.021.07618.7333
Slightly volatile
Cash Per Share1.441.52173.5316
Slightly volatile
Capex To Operating Cash Flow0.01350.01420.1201
Slightly volatile
Days Payables Outstanding154162236
Pretty Stable
Net Current Asset Value37.1 M35.3 M38.1 M
Very volatile
Income Quality0.990.65580.9046
Slightly volatile
Tangible Asset Value76.5 M72.9 M88 M
Pretty Stable
Intangibles To Total Assets0.50.43280.4504
Pretty Stable
Current Ratio0.450.478440.3483
Slightly volatile
Receivables Turnover6.56.84718.6362
Pretty Stable
Graham Number7.658.052279
Slightly volatile
Shareholders Equity Per Share0.460.4834201
Slightly volatile
Debt To Equity7.47.04661.192
Slightly volatile
Average Receivables86.5 K90.1 K137 K
Slightly volatile
Revenue Per Share0.530.55751.6465
Slightly volatile
Interest Debt Per Share6.743.92385.4274
Pretty Stable
Debt To Assets0.640.610.2159
Slightly volatile
Operating Cycle281267166
Pretty Stable
Price Book Value Ratio0.661.21551.5429
Slightly volatile
Days Of Payables Outstanding154162236
Pretty Stable
Ebt Per Ebit0.91.67841.1269
Pretty Stable
Company Equity Multiplier12.1311.55192.6885
Slightly volatile
Long Term Debt To Capitalization0.210.14680.1688
Very volatile
Total Debt To Capitalization0.920.87570.2764
Slightly volatile
Debt Equity Ratio7.47.04661.192
Slightly volatile
Quick Ratio0.310.329540.1065
Slightly volatile
Dividend Paid And Capex Coverage Ratio73.7370.222634.5321
Very volatile
Net Income Per E B T1.441.431.0559
Slightly volatile
Cash Ratio0.30.312731.8392
Slightly volatile
Days Of Inventory Outstanding225214107
Slightly volatile
Days Of Sales Outstanding50.6453.308557.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.831.01421.1745
Very volatile
Price To Book Ratio0.661.21551.5429
Slightly volatile
Fixed Asset Turnover0.770.72880.3904
Very volatile
Capital Expenditure Coverage Ratio73.7370.222634.5321
Very volatile
Debt Ratio0.640.610.2159
Slightly volatile
Price Sales Ratio1.01.0538163
Pretty Stable
Asset Turnover0.10.09980.0331
Pretty Stable
Price Fair Value0.661.21551.5429
Slightly volatile

VBI Vaccines Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.7 M9.1 M255.7 M
Pretty Stable
Working Capital37.1 M35.3 M38.1 M
Very volatile

VBI Fundamental Market Drivers

Cash And Short Term Investments23.7 M

VBI Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About VBI Vaccines Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include VBI Vaccines income statement, its balance sheet, and the statement of cash flows. VBI Vaccines investors use historical funamental indicators, such as VBI Vaccines's revenue or net income, to determine how well the company is positioned to perform in the future. Although VBI Vaccines investors may use each financial statement separately, they are all related. The changes in VBI Vaccines's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VBI Vaccines's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on VBI Vaccines Financial Statements. Understanding these patterns can help to make the right decision on long term investment in VBI Vaccines. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10.9 M11.4 M
Total Revenue8.7 M9.1 M
Cost Of Revenue14.5 M15.2 M
Stock Based Compensation To Revenue 0.77  0.73 
Sales General And Administrative To Revenue 4.85  4.61 
Research And Ddevelopement To Revenue 1.08  1.02 
Capex To Revenue(0.1)(0.10)
Revenue Per Share 0.56  0.53 
Ebit Per Revenue(6.37)(6.69)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:
Check out the analysis of VBI Vaccines Correlation against competitors.
For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for VBI Stock analysis

When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Directory
Find actively traded commodities issued by global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.03)
Revenue Per Share
0.558
Quarterly Revenue Growth
1.911
Return On Assets
(0.29)
Return On Equity
(2.59)
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.